Previous 10 | Next 10 |
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present data from its clinical test - NeXT Dx TM - at the virtual AMP Annual Meeting from Nov 16-20, 2020. The poster presentation, titled “An exome and transc...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting online, November 11-14, including poster presentations on November 11 ...
Personalis, Inc. (PSNL) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET Company Participants Caroline Corner – Investor Relations John West – President and Chief Executive Officer Aaron Tachibana – Chief Financial Officer Conference Call Participants Ivy X. M...
Personalis (PSNL): Q3 GAAP EPS of -$0.27 beats by $0.01.Revenue of $19.8M (+15.5% Y/Y) beats by $0.74M.Shares -4.2% AH.Press Release For further details see: Personalis EPS beats by $0.01, beats on revenue
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the third quarter ended September 30, 2020. Third Quarter Highlights Reported record revenues of $19.8 million in the third quarter of ...
Lung cancer diagnostics company, Biodesix (BDSX) has priced initial public offering of ~4.17M common shares at $18/share.Underwriters' over-allotment is an additional 600K shares.Trading commences today on Nasdaq.Offering is expected to close on October 30.Net proceeds of ~$30M will be u...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its third quarter 2020 financial results after the market closes on Thursday, November 5, 2020. In conjunction with the release, the Company will host a conference call and webcast...
As the pandemic resurges, early vaccine trials are reaching the home stretch. Vaccine results now pushed back to mid-to-late November at the earliest, and there have been delays in therapeutic treatments. Healthcare overall has been burdened by the uncertainty on the Affordable Ca...
Gainers: [[ALGS]] +17.2%. [[FLDM]] +11.1%. [[SELB]] +9%. [[SOS]] +5.2%. [[PSNL]] +4%.Losers: [[TCOM]] -8.5%. [[FISV]] -6%. [[SCS]] -5.4%. [[LOOP]] -5.4%. [[AGIO]] -4.4%. For further details see: FISV, TCOM, FLDM and SELB among after-hours movers
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the company’s participation at the Immuno Series US Virtual meeting which will be held online, October 15-16, 2020. Personalis will present “Maximizing immunotherapy biomarke...
News, Short Squeeze, Breakout and More Instantly...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tum...